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Abstract
Recently, the ﬁrst outbreak of clonally related VIM-2 metallo-b-lac-
tamase (MBL)-producing Pseudomonas aeruginosa in a Dutch ter-
tiary-care centre was described. Subsequently, a nationwide
surveillance study was performed in 2010–2011, which identiﬁed
the presence of VIM-2 MBL-producing P. aeruginosa in 11 different
hospitals. Genotyping by multiple-locus variable-number tandem-
repeat analysis (MLVA) showed that the majority of the 82 MBL-
producing isolates found belonged to a single MLVA type (n = 70,
85%), identiﬁed as ST111 by multilocus sequence typing (MLST). As
MBL-producing isolates cause serious infections that are difﬁcult to
treat, the presence of clonally related isolates in various hospitals
throughout the Netherlands is of nationwide concern.
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Introduction
Resistance to the carbapenems in Pseudomonas aeruginosa is
most often due to the loss of the outer membrane protein
OprD, the over-expression of efﬂux systems or a combina-
tion of both [1]. However, since the 1990s there has been a
substantial increase in the reporting of metallo-b-lactamases
(MBLs) among carbapenem-resistant P. aeruginosa isolates
globally [2]. MBLs are capable of hydrolyzing most of the b-
lactam antibiotics and MBL-encoding genes are usually
located on integrons that frequently carry additional genes
encoding for resistance to non-b-lactam antibiotics, resulting
in multidrug resistance (MDR). Currently, the most prevalent
and widespread MBL genes in P. aeruginosa are the VIM and
IMP types; in particular, VIM-2 has become the dominant
MBL type among P. aeruginosa worldwide [2].
The Netherlands is considered to be a low-prevalence
country for antimicrobial resistance [3], and the reporting of
MBLs among P. aeruginosa has been rare. However, a recent
study at a tertiary-care centre identiﬁed a large number of
VIM-2 MBL-producing P. aeruginosa isolates [4]. Genotyping
by multiple-locus variable-number tandem-repeat analysis
(MLVA) demonstrated one main cluster, suggesting the pres-
ence of a common source and/or nosocomial transmission.
In the present study, we collected P. aeruginosa isolates non-
susceptible to imipenem or meropenem according to the
EUCAST 2010 recommendations (http://www.eucast.org)
from 21 laboratories (c. 30% of the Dutch laboratories) serv-
ing over 30 hospitals, including three university teaching hos-
pitals and various large community teaching hospitals, to
assess the occurrence of MBL-producing P. aeruginosa in the
Netherlands.
In total, 206 non-repeat isolates that were either retro-
spectively stored or prospectively collected from clinical and
screening specimens between November 2009 and May 2011
were included. Isolates from cystic ﬁbrosis patients were
excluded. Identiﬁcation to the species level was performed by
oxidase activity (DrySlideTM Oxidase; Becton Dickinson,
Franklin Lakes, NY, USA) and resistance to C390 (DIAT-
ABS; Rosco Diagnostica A/S, Taastrup, Denmark). Of iso-
lates susceptible to C390, further identiﬁcation was
performed by VITEK 2 (VITEK AMS; bioMe´rieux VITEK Sys-
tems Inc., Hazelwood, MO, USA). Antibiotic susceptibility was
determined by disk diffusion (Oxoid Ltd, Basingstoke, UK)
using EUCAST 2010 breakpoints (http://www.eucast.org).
Isolates that were positive in a phenotypic screening test
for MBL production (i.e. imipenem and doripenem combo
disk test with EDTA) [5], were tested by PCR for the
presence of blaVIM and blaIMP genes [6]. Sequencing of the
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genes was performed using the class 1 integron primers 5CS
(5¢-GGC ATC CAA GCA GCA AG-3¢) and 3CS (5¢-AAG
CAG ACT TGA CCT GA-3¢) in combination with IMP and
VIM primers, as previously described [7]. Isolates that were
negative in the phenotypic screening test and isolates that
were phenotypically positive but negative for blaVIM or blaIMP
were further evaluated for carbapenemase activity by a mod-
iﬁcation of the bioassay of Masuda et al. [8] using a solution
containing 50 mg/L imipenem on Mueller–Hinton agar plates,
inoculated with Escherichia coli ATCC 25922 as described
before [9]. Genotyping of all MBL-producing isolates was
performed by MLVA as described by van Mansfeld et al. [10]
using the MLVA9-Utrecht protocol. Additionally, MLST was
performed using seven conserved housekeeping genes for
P. aeruginosa (acsA, aroE, guaA, mutL, nuoD, ppsA and trpE)
(http://pubmlst.org/paeruginosa/). All tests, except MLST,
were performed in a centralized laboratory at the Erasmus
University Medical Centre.
In total, 77 isolates tested positive in the phenotypic
screening test, of which 76 carried blaVIM. The isolate that
was negative for both blaVIM and blaIMP was considered fal-
sely screen positive because carbapenemase activity was
excluded by the modiﬁed bioassay. Of the 129 isolates that
were negative in the phenotypic screening test, six were
positive for carbapenemase activity in the bioassay. All six
isolates carried blaVIM, resulting in 82 (40%) MBL-producers.
Most of the isolates were isolated from the respiratory tract
(n = 70, 34%); 32 (16%) were isolated from urine, 11 (5%)
from blood, 22 (11%) from soft tissue or bone, 13 (6%) from
intra-abdominal specimens and 45 (22%) from various other
specimens. For 13 isolates (6%) the specimen site was
unknown. MBL-producing P. aeruginosa were more often iso-
lated from patients admitted to an ICU (51% vs. 36%,
p = 0.05) and were more resistant than non-MBL-producing
isolates (p < 0.01, Fig. 1). MBL-producing isolates were
detected in eight hospitals, two burn wound centres, one
long-term healthcare facility and in two community patients
attending a general practitioner. The majority of the care
facilities with MBL-producing isolates were located in the
western part of the Netherlands, and ﬁve of these care facili-
ties had more than one patient with an MBL-producing iso-
late within the same ward.
Among the MBL-producing isolates, MLVA identiﬁed one
large cluster consisting of 36 patients (MLVA 364) and a few
closely related clusters consisting of 13 patients (MLVA 255),
seven patients (MLVA 382) and four patients (MLVA 404),
and nine closely or possibly related small clusters consisting
of one or two patients each (Fig. 2). This large cluster of clo-
sely and possibly related isolates was present in all of the
care facilities with MBL-producing isolates. MLST identiﬁed
this large cluster as sequence type (ST) 111. MLVA also
demonstrated a non-related cluster consisting of 11 patients
(MLVA 68 and MLVA 409), identiﬁed by MLST as ST446.
This smaller cluster was only present in one university hospi-
tal. There was also one patient with an MBL-producing iso-
late that was not related to any of the other isolates (MLVA
384). This patient attended a general practitioner in the
north-eastern part of the Netherlands. Sequencing of 25 ran-
domly selected isolates among all major MLVA types
revealed the following gene cassettes in all 25 isolates:
aacA29a, blaVIM-2 and aacA29b in the same order as previ-
ously described [11].
The Netherlands has so far succeeded in keeping the inci-
dence of major resistant nosocomial pathogens at a low
level, [3] due to a combination of low antibiotic pressure in
human healthcare [12] and the implementation of national
prevention guidelines to minimize the nosocomial spread of
resistant bacteria. The low incidence of methicillin-resistant
Staphylococcus aureus (MRSA) is an example of the success of
Dutch measures to prevent and control infection and trans-
mission [13]. The presence of a multi-resistant VIM-2-MBL-
producing P. aeruginosa clone in several hospitals in the
Netherlands is therefore remarkable.
Pseudomonas aeruginosa has a non-clonal structure with a
huge diversity of sequence types (STs) and nosocomial
P. aeruginosa infections or colonization have generally been
characterized by polyclonality [14]. In this study we only
identiﬁed two sequence types among the MBL-producing
P. aeruginosa, of which ST111 was the major type found.
ST111 belongs to the international clonal complex CC111
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FIG. 1. Resistance % for 206 carbapenem non-susceptible Pseudomo-
nas aeruginosa isolates isolated from various care facilities in the
Netherlands, from November 2009 to May 2011. IMP, imipenem;
MEM, meropenem; PIP, piperacillin; CAZ, ceftazidime; TOB, tobra-
mycin; AMK, amikacin; CIP, ciproﬂoxacin; AZT, aztreonam; COL,
colistin.
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has mostly been described in Europe as the major European
multi-resistant P12 clone that has been associated with the
emergence, spread and persistence of MDR strains in hospi-
tals, mainly ICUs [14–17]. ST446 seems less widespread than
ST111, but has also been described among MDR isolates in
France and Spain [15,17].
The source and transmission modes of this particular
P. aeruginosa strain in the Netherlands are currently unknown.
The fact that most of the patients with an MBL-producing iso-
late were admitted to an ICU, a setting that is characterized
by an increased risk of cross-transmission and high antimicro-
bial pressure [18], might have favoured clonal spread. Addi-
tionally, all Dutch hospitals are connected by referred
patients who have the potential to facilitate dissemination of
MDR organisms between hospitals [19]; subsequently,
patients might serve as important reservoirs and transmission
sources, stressing the importance of hand hygiene compliance,
which was only 20% in a recent observational study in 24
Dutch hospitals [20], and patient precautions.
Since MBL-producing isolates can cause serious infections
that are difﬁcult to treat, their presence in various hospitals
in the Netherlands is of nationwide concern. In the absence
of new agents for the treatment of infections caused by
these bacteria, the spread of this particular clone may lead
to treatment failures with increased morbidity and mortality.
Therefore, MBL-producing P. aeruginosa require rapid identiﬁ-
cation and the timely implementation of infection control
measures in combination with systematic surveillance to
monitor its potential clonal spread.
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FIG. 2. MLVA genotyping of MBL-producing P. aeruginosa isolates of 82 patients from various care facilities in the Netherlands, from November
2009 to May 2011, shows one large cluster of 70 patients, a smaller cluster of 11 patients (no. 68 and 409), and a single strain unrelated to any
of the three clusters (no. 384).
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